Latest Conference Articles

AI Diagnostics Fall Short in Skin of Color

AI Diagnostics Fall Short in Skin of Color

April 27th 2021

Skin of Color Update

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

Tips to Improve High-Risk Skin Cancer Management

Tips to Improve High-Risk Skin Cancer Management

April 26th 2021

American Academy of Dermatology

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application

Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application

April 26th 2021

American Academy of Dermatology

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

‘Zoom Dysmorphia’ Becoming Rising Issue Among Patients

‘Zoom Dysmorphia’ Becoming Rising Issue Among Patients

April 26th 2021

American Academy of Dermatology

A survey found a large proportion of dermatologists surveyed said their patients referenced video conferencing as the reason for seeking cosmetic consultation since the start of the pandemic.

Bimekizumab Beats Secukinumab in Skin Clearance for Psoriasis

Bimekizumab Beats Secukinumab in Skin Clearance for Psoriasis

April 26th 2021

American Academy of Dermatology

In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.

Otezla Phase 3 ADVANCE Trial Reports Improvement in Plaque Psoriasis Severity

Otezla Phase 3 ADVANCE Trial Reports Improvement in Plaque Psoriasis Severity

April 25th 2021

American Academy of Dermatology

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Phase 2 Study of Ruxolitinib Cream for Vitiligo Announces New Findings

Phase 2 Study of Ruxolitinib Cream for Vitiligo Announces New Findings

April 25th 2021

American Academy of Dermatology

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

Game Changers in Dermatology

Game Changers in Dermatology

April 25th 2021

American Academy of Dermatology

Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.

Tremfya Phase 3 Data Show Continued Clearance After 5 Years

Tremfya Phase 3 Data Show Continued Clearance After 5 Years

April 25th 2021

American Academy of Dermatology

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

New Officers, Board Members Elected to AAD

New Officers, Board Members Elected to AAD

April 25th 2021

American Academy of Dermatology

The American Academy of Dermatology Announced the results from its annual election, with 2 officers and 4 board members assuming their new positions in March 2022.